Background:  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients Trial Registration No: NCT01870778 ( Link  Trial Status: Recruitment stopped, study finished Randomized in Basel 30 patients, worldwide 6800 patients Enrolling Centers:  542 centers Worldwide Core Study Team: 
© Christian Mueller, 2012 - 2020 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: July 2020
Dr. Beate Hartmann Lorraine Sazgary Dr. Christian Puelacher Home News Team Studies Publications Events Cooperations Contact